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Supplementary Methods 
 
Study design, rationale, and overall conduct 
The EPIC study was a competitive research cooperative agreement announced by the Centers for 
Disease Control and Prevention (CDC) in 2009.  The study was conducted for 2.5 years based on 
the availability of research funds.  Final sites were selected based on an objective review of site 
capability to conduct the study.  The primary objective of the study was to determine the 
incidence and etiology of community-acquired pneumonia requiring hospitalization among U.S. 
adults.  Several factors were assessed by the evaluation of external referees and while geographic 
representation was one of them, capacity to enroll a sufficient number of patients, collect and test 
specimens, and provide denominator data for incidence calculations were deemed most 
important to the success of the study.   
 
The final study hospitals chosen to participate in the study represent a mix of hospital types.  
Northwestern Memorial Hospital, Rush University Medical Center, and Vanderbilt University 
Medical Center are all academic medical centers.  John H. Stroger, Jr. Hospital of Cook County 
is a public urban teaching hospital and University of Tennessee Health Science Center/Saint 
Thomas Health is not-for-profit teaching community hospital.    
 
The EPIC study was designed as a prospective, multicenter, population-based, active 
surveillance study.  Together, CDC and site Principal Investigators wrote the study protocol, 
created the data collection instruments, and developed standard operating procedures.  Annual 
site visits and investigator meetings took place from 2009 through 2013.  Investigator and study 
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coordinator calls were held weekly to monitor study conduct (e.g. enrollment, laboratory 
procedures, etc.), troubleshoot issues, and maintain standardization among sites.    
 
The initial design did not include control enrollment.  However, after one complete season of 
case enrollment, CDC and site Principal Investigators, felt that because the EPIC study used real-
time polymerase chain reaction (PCR) for the detection of respiratory viruses, Mycoplasma 
pneumoniae, and Chlamydophila pneumoniae from naso/oropharyngeal (NP/OP) swabs, it would 
be useful to enroll asymptomatic controls to help understand the significance of molecular 
detection of pathogens, especially human rhinovirus, which can be shed for >2weeks after an 
infection.1  Thus, the inclusion of controls was intended to identify the background prevalence of 
these respiratory pathogens in the upper airway among asymptomatic adults and compare it with 
the prevalence of respiratory pathogens in enrolled adults hospitalized with pneumonia.  With the 
resources available, only one adult study hospital was able to enroll a convenience sample of 
adults without pneumonia who presented for non-acute care in the general medicine clinic.  
While the emergency department (ED) was explored as a setting for enrollment, it was not 
feasible to enroll asymptomatic individuals from the ED, and thus we opted for a primary care 
clinic.  While we present the overall proportion of detections in controls, our pathogen-specific 
incidence estimates were not adjusted based on detection in controls.   
 
Detailed inclusion and exclusion criteria definitions 
The Methods section in the manuscript outlines the inclusion and exclusion criteria.  Here, we 
provide more detailed definitions of certain criteria as appropriate.  Fever and hypothermia were 
defined as temperature ≥38˚C and <35.5˚C respectively.  White blood cell count (wbc) was 
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compared to baseline if available and defined as leukocytosis (wbc >11,000/mm3) or leukopenia 
(wbc <3000/mm3).2  Tachypnea was defined as respiratory rate >25 breaths/minute.   
 
Adults who were immunocompetent and had recent hospitalization <28 days were excluded.  
Adults with immunosuppression and recent hospitalization <90 days were excluded; 
immunosuppression was defined as solid organ or hematopoietic stem cell transplant, cancer on 
chemotherapy, or steroid use (prednisone equivalent of 20 mg/day) for >30 days.   
 
In addition to recent hospitalization, we excluded adults who had been enrolled in the EPIC 
study within the previous 28 days, or were functionally-dependent nursing home residents, or if 
they had a clear alternative diagnosis.  Functional status of nursing home patients was assessed at 
time of screening using the Activities of Daily Living (ADL) Scale;3 adults with score >7 were 
not considered independent and thus excluded.  Examples of clear alternative diagnoses include 
admission for foreign body aspiration or known drug overdose.  Lastly, we also excluded the 
following patients with specific conditions, either because they were considered to be severely 
immunosuppressed or they had a condition that is a known risk factor for non-community-
acquired respiratory pathogens: tracheotomy, percutaneous endoscopic gastrostomy tube, cystic 
fibrosis, cancer with neutropenia, solid organ or hematopoietic stem cell transplant ≤90 days 
earlier, active graft versus host disease or bronchiolitis obliterans, or human immunodeficiency 
virus infection with CD4 cell count <200 cells/mm3.4  Neutropenia was defined as an absolute 
neutrophil count <500/mm3.   
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Data collection and cleaning 
Study staff at each site was extensively trained in screening, interviewing, and chart review prior 
to study initiation.  CDC conducted annual site visits to each study site and performed yearly 
random audits to evaluate data quality and consistency of data collection from site to site. 
 
Adults and/or their caregivers were interviewed by trained staff as soon as possible after 
enrollment (within 24 hours) using a standardized questionnaire that included demographics, 
clinical presentation, antimicrobial use prior to hospitalization, and underlying medical 
conditions.   
 
Medical chart abstraction was performed after discharge to obtain information on admission and 
discharge timing, antimicrobials received during hospitalization, underlying medical conditions, 
vital signs, select laboratory results including routine microbiology, and outcomes including 
intensive care, mechanical ventilation, and death.   
 
Once all data was entered into the centralized database, systematic data checks were performed 
to detect outliers and errors, which were corrected to create a final dataset. 
 
Vaccination verification 
Vaccination data for influenza and S. pneumoniae were self-reported and then verified through 
use of vaccine registries, medical record review (inpatient and outpatient), and non-traditional 
providers (pharmacy) when possible.   
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Specimen collection, processing, and testing 
Blood for culture was collected in BACTEC bottles, transported to the microbiology laboratory, 
and tested on site per routine methods.  Initial blood cultures were usually obtained prior to 
enrollment as part of standard care, in contrast with most other specimens which were usually 
obtained for research purposes [urine, serology, sputum, and NP/OP swabs] and therefore after 
informed consent; in some cases, urine and sputum were also collected for clinical care but this 
was not standard at all hospitals.  Blood for serology was collected in a Vacutainer tube and 
immediately stored at 4°C for 1-18 hours after collection before being centrifuged, aliquoted, and 
stored in Sarstedt tubes at -20°C.  Urine was collected in a standard sterile specimen cup and 
refrigerated at 2-8°C.  BinaxNOW urine antigen testing for Legionella pneumophila and 
Streptococcus pneumoniae occurred on site following the manufacturers recommendations.5,6  
Urine was refrigerated at 4°C for up to 48 hours after collection, and then aliquoted, and stored at 
-70°C.   
 
NP/OP specimens were collected using sterile flocked Dacron (NP) or wound rayon (OP) swabs 
with flexible shafts.  NP swabs were passed through one nostril to the nasopharynx and rotated to 
collect epithelial tissue and absorb secretions and OP swabs were inserted into the posterior 
pharynx and tonsillar areas.  NP/OP swabs were combined in 3 ml sterile universal transport 
medium and refrigerated at 4°C for up to 48 hours, aliquoted, and stored at -70°C.  PCR assays 
were performed on total nucleic acid extracted from NP/OP swabs at each site using CDC 
developed methods;7-9 quality assurance and monitoring protocols maintained procedural 
standardization among sites.10,11  For all NP/OP PCR assays, a cycle threshold value <40 was 
considered positive.    
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When available, sputum, endotracheal aspirates (ETA), bronchoalveolar-lavage (BAL) 
specimens, and pleural fluid (PF) were collected into sterile containers; gram stain and bacterial 
culture were performed on site per routine clinical care.  Only bacterial culture from sputum and 
ETA of high quality (≤10 epithelial cells/low power field [lpf] and ≥25 white blood cells/lpf) 
were included.12  However, legionella PCR results from a sputum specimen of any quality were 
included.5,7  BAL specimens with significant growth of potential pathogens by semi-quantified 
(>3+ growth, moderate to heavy growth) or quantified (>103 colony forming units/ml) methods 
were included.4,12   
 
After routine testing, PF was refrigerated at 4°C for up to 48 hours, aliquoted, and stored at -
70°C.  Frozen samples were then sent to CDC and once tested at CDC, were sent on dry ice to 
the University of Utah.  PF PCR targeting S. pneumoniae (lyt-A) and Streptococcus pyogenes 
(spy) genes was performed at CDC.13  PF specimens were then tested at the University of Utah 
for bacterial pathogens using the following PCR methods: 1) bench-top nested PCR assays14 
(Haemophilus influenzae [rpoB, bexA]), Staphylococcus aureus [nuc, mecA], S. pneumoniae 
[lytA], S. pyogenes [speB], and 2) FilmArray® blood culture panel15 (Acinetobacter baumanii, 
Escherichia coli, Fusobacterium, H. influenzae, Klebsiella pneumoniae, pseudomonas, S. 
aureus, S. pneumoniae, S. pyogenes, viridans streptococci). 
 
Frozen specimens (sera, NP/OP swabs, PF, urine, sputa), including bacterial isolates, were 
transported on dry ice to CDC for testing, quality control, and long-term storage at -70°C.   
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Laboratory quality control and validation of real-time PCR 
CDC provided qualified PCR primers, probes, and reagents to each site, and CDC staff reviewed 
methods and trained laboratory staff at each site to standardize techniques.  Prior to performing 
laboratory analyses, each site completed an external quality assessment program provided by 
Quality Control for Molecular Diagnostics (QCMD) (http://www.qcmd.org/)10,11 and completed 
CDC influenza proficiency testing.  A random sample of 10% of all NP/OP swabs from every 
month of the first year of the study, were also tested at CDC, the results of which demonstrated 
99% agreement with site-specific data for all viral and atypical bacterial targets.         
 
Blood and sputa contaminants 
Certain bacteria isolated from blood were considered contaminants and unrelated to community-
acquired pneumonia.  These included Aeroccocus, Alcaligenes faecalis, Bacillus, Citrobacter, 
coagulase-negative Staphylococcus, Corynebacterium, Enterococcus, Micrococcus, Neisseria 
subflava, Propionibacterium, Stomatococcus, Streptococcus bovis, and Veillonella. Candidemia 
was not considered to be related to community-acquired pneumonia.   
 
More virulent viridans streptococci (S. anginosus, S. mitis) were considered to be pathogens.  
Less virulent viridans streptococci (S. salivarius and viridans streptococci without further 
speciation) were considered contaminants when isolated concurrently with a bacterial pathogen 
or if only one of two simultaneously collected blood cultures was positive.  Otherwise, less 
virulent viridans group streptococci were considered to be pathogens.   
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For high-quality sputum bacterial cultures, the following were not considered clinically 
associated with community-acquired pneumonia: Aspergillus species, Enterococcus species, 
viridans group streptococci, and yeast.   
 
Fungal and mycobacterial detections 
 
Mycobacterium tuberculosis was considered a pathogen if detected in any acid-fast bacilli (AFB) 
sputum specimen.  Nontuberculous mycobacterial (NTM) disease was assessed based on 
American Thoracic Society/Infectious Diseases Society of America guidelines;16 NTM disease 
was included if there was a positive AFB culture with a NTM pathogen from at least two 
separate expectorated sputum samples (of any quality) or one positive culture from a BAL in the 
setting of radiographic findings consistent with pneumonia in an adult.16  Fungal pathogens were 
determined per clinical guidelines.17    
 
Influenza and other respiratory virus serology methods 
 
All serology was performed at CDC on available paired acute-phase (obtained at enrollment) and 
convalescent-phase (obtained 3-10 weeks after enrollment) serum specimens.  Serology for non-
influenza respiratory viruses (adenovirus, human metapneumovirus, respiratory syncytial virus, 
and parainfluenza viruses 1,2,3 [PIV]) was performed using CDC developed indirect IgG 
enzyme immunassays.18,19  A ≥4-fold rise in IgG antibody titer between the paired acute-phase 
and convalescent-phase serum specimens was considered evidence of current or recent infection.  
Due to antigenic cross-reactivity among PIV 1-3, data from all three types were analyzed in 
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aggregate.  Results were considered inconclusive and excluded from the analysis if paired sera 
exhibited: 1) high background signal to the uninfected control cells or 2) differences in antibody 
levels identified among 4 or more virus assays indicating possible mismatches in the serum pairs 
between patients.   
 
For influenza serology, hemagglutination inhibition (HI) assays were performed for both 
influenza A and B viruses, and microneutralization (MN) assays were subsequently performed 
on all specimens that were originally positive for influenza B virus by HI assay.20  Influenza 
serology was performed on paired sera for the following strains circulating during 2010-2012: 
A/California/07/2009 (H1N1), A/Perth/16/2009 (H3N2), B/Brisbane/60/2008 (Victoria lineage), 
and B/Florida/4 (Yamagata lineage).   
 
HI assays were performed with 0.5% turkey red blood cells (RBCs).  Serum samples were 
treated with receptor destroying enzyme and adsorbed with turkey RBCs to eliminate the non-
specific agglutinins as needed.  Two-fold dilutions of sera with a starting dilution of 1:10 were 
incubated with a standard amount of virus (4HAU/25 µL).20  An HI titer was defined as the 
reciprocal of the highest serum dilution that completely inhibited hemagglutination.  For 
influenza A virus HI assays, whole viruses were utilized; for influenza B virus HI assays, ether- 
treated antigens were used to improve the assay sensitivity.21,22  All specimens that were positive 
for influenza B virus in the HI assay using ether-treated antigens were further tested by MN 
assay to verify specificity.  The influenza B virus MN assays were performed by incubating two-
fold serial dilutions of heat-inactivated sera (starting dilution 1:10), with 100 tissue culture 
infection dose 50 (TCID50) of influenza B viruses.  The virus-serum mixture was then used to 
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infect Madin-Darby canine kidney (MDCK) cells.  After 18-20 hours incubation, the presence of 
viral protein was detected by enzyme-linked immunosorbent assay (ELISA) with a monoclonal 
antibody specific to the nucleoprotein of the influenza B viruses.  MN titers were defined as the 
reciprocal of the highest dilution of serum that gave 50% neutralization.  
 
Influenza seroconversion was considered a 4-fold rise in titer for paired acute-phase and 
convalescent-phase sera with a convalescent titer achievement of ≥40.  The final determination 
of influenza serology accounted for influenza vaccination status and timing based on data from 
self/caregiver report and the vaccine verification process.23  If influenza serology results 
indicated seroconversion when vaccine was administered within 2 weeks (based on 
self/caregiver report or vaccine verification) before acute-phase serum collection, or between 
acute-phase and convalescent-phase serum collections, results were deemed inconclusive.  Thus, 
influenza serology results were considered positive when there was ≥4-fold rise to influenza A 
(by HI titer) and/or B (by both HI and MN titer) virus with a convalescent titer ≥40 in adults who 
did not receive influenza vaccine or received vaccine more than 2 weeks prior to acute-phase 
serum collection and not between acute-phase and convalescent-phase sample collection. 
 
Radiographic definitions and process 
For enrollment into the study, adults were required to have chest radiography consistent with 
pneumonia within 48 hours of admission.  The initial interpretation of the admission chest 
radiograph was made by clinicians providing care for the patient including but not limited to a 
resident, general medicine or sub-specialty attending, emergency room physician, or radiologist 
on call.  The initial radiographic enrollment criteria were purposefully sensitive to avoid missing 
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any possible cases of pneumonia.  However, it is known that there is variability in the clinical 
interpretation of chest radiography among clinicians and depending on their level of training in 
radiology.24  To minimize these biases and increase the specificity of the case definition, 
independent confirmation by one board certified chest radiologist (study radiologists FC, EH) at 
each site who was blinded to demographic and clinical information was required for final 
inclusion in the study.  Available chest radiographs prior to the current hospitalization were used 
for comparison.  Each of the study radiologists used the same form for recording their 
interpretation.  Radiographic pneumonia was defined as consolidation (a dense or fluffy opacity 
with or without air bronchograms), infiltrate (linear and patchy alveolar or interstitial densities), 
or pleural effusion.24-26  Edema was defined as manifestation by Kerley A and B lines due to 
fluid in the interlobular space and was not included in the definition of infiltrate.  Upon review of 
a 10% random sample of radiographs, inter-rater percent agreement between the two study 
radiologists was 86% (CI 81-89%).   
 
The study design did assume that the treating clinicians radiographic read was sensitive and that 
the study radiologist read was more specific and thus, the study radiologist was screening out 
false-positives.  This allows for the possibility that we missed radiographic cases that were not 
detected by the treating clinicians; however, there were not ample resources to review all 
radiographs initially deemed to be negative.     
 
Counties under surveillance and incidence calculation inputs 
States and counties under surveillance from each site were as follows: 
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1) Chicago site: John H. Stroger, Jr. Hospital of Cook County, Northwestern Memorial Hospital, 
Rush University Medical Center (all in Chicago, IL) – Illinois: Cook county  
2) Nashville site: University of Tennessee Health Science Center/Saint Thomas Health, 
Vanderbilt University Medical Center (both in Nashville, TN) - Tennessee: Cheatham, Davidson, 
Dickson, Montgomery, Robertson, Rutherford, Sumner, Williamson, and Wilson counties 
 
The source of market share data varied between sites.  The data source for TN counties was the 
TN Hospital Discharge Data System, an electronic data collection system that includes 
administrative data from all hospital admissions and emergency department visits in TN.  By 
state mandate, data collected from all TN non-federal hospitals include dates of admission and 
discharge, discharge diagnoses, and patient date of birth along with gender, race, and ethnicity, 
among other variables.  IL market share for the study hospitals was obtained through an IL 
Hospital Association CompData sharing agreement with the EPIC investigators for Cook County 
residents admitted to any IL hospital.  For market share, pneumonia admissions were based on 
International Classification of Diseases, 9th Revision, Clinical Modification discharge diagnosis 
codes 480-486, 487.0, and 510 and were collected by age group.27 
Enrollment city Population* 
under 
surveillance, 
2010 
Population* 
under 
surveillance, 
2011 
Population* 
under 
surveillance, 
2012 
Percent 
market share, 
year 1† 
Percent 
market share, 
year 2† 
Chicago  3,969,474 3,992,029 4,015,945 8.7% 9.6% 
Nashville 1,264,326 1,286,082 1,316,560 18.1% 18.7% 
*Population of adults ≥18 years old 
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† Annual incidence rates were calculated from July 1, 2010 to June 30, 2011 (year 1) and July 1, 
2011 to June 30, 2012 (year 2) 
 
Enrollment Validation 
To assess for selection bias during the enrollment process, we compared eligible adults who were 
enrolled with those who were not enrolled.  Variables included age, race and ethnicity, gender, 
and outcomes including length of stay, intensive care admission, mechanical ventilation, and 
death.  Bivariate analysis was conducted using the chi-square, Fisher’s exact, or Wilcoxon rank-
sum test for categorical and continuous variables as appropriate (P <0.05). 
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Supplemental Results 
Supplemental Table S1: Characteristics of Hospitalized Adults with Community-acquired Pneumonia: Comparison of All 
Eligible Adults, All Enrolled Adults, and Adults with Radiographic Confirmation of Pneumonia 
Characteristic Eligible 
adults who 
were not 
enrolled*  
(n=943) 
Enrolled adults 
who did not 
withdraw  
 
(n=2481) 
Adults with 
radiographic 
pneumonia 
 
(n=2320) 
Adults with 
radiographic 
pneumonia during 
incidence period† 
(n=2061) 
Female sex – no. (%) 498 (53) 1276 (51)  1190 (51) 1070 (52) 
Race and ethnicity – no. (%) 
   Non-Hispanic white 
   Non-Hispanic black 
   Hispanic 
   Other 
 
443/922 (48) 
329/922 (36) 
99/922 (11) 
51/922 (6) 
 
1177 (47) 
955 (39) 
254 (10) 
95 (4) 
 
1086 (47) 
898 (39) 
243 (10) 
93 (4) 
 
971 (47) 
789 (38) 
216 (10) 
85 (4) 
Age groups – no. (%) 
   18-49 years 
 
193 (20) ‡ 
 
740 (30) 
 
701 (30) 
 
621 (30) 
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   50-64 years 
   65-79 years 
   ≥ 80 years 
249 (26) ‡ 
259 (27) ‡ 
242 (26) ‡ 
836 (34) 
560 (23) 
345 (14) 
787 (34) 
517 (22) 
315 (14) 
699 (34) 
458 (22) 
283 (14) 
Illness onset to presentation – median days, 
(interquartile range, IQR) 
NA§  4 (2-7) 
(n=2478) 
4 (2-7) 
(n=2317) 
4 (2-8) 
(n=2058) 
Symptoms – no. (%) 
   Cough    
   Dyspnea 
   Fever/feverish 
NA  
2169 (87) 
1942 (78) 
1677 (68) 
 
2029 (88) 
1808 (78) 
1572 (68) 
 
1808 (88) 
1629 (79) 
1406 (68) 
Any underlying condition¶  – no. (%) 
   Chronic lung disease     
   Chronic heart disease 
   Immunosuppression 
   Diabetes mellitus 
NA 1959 (79) 
1055 (43) 
882 (36) 
739 (30) 
656 (26) 
1817 (78) 
968 (42) 
810 (35) 
685 (30) 
597 (26) 
1614 (78) 
873 (42) 
708 (34) 
606 (29) 
532 (26) 
Hospital indicators – no. (%) 
   Length of stay – median days, IQR 
 
3 (2-7) ‡ 
 
3 (2-6) 
 
3 (2-6) 
 
3 (2-6) 
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   CURB-65║ – median, IQR 
          0-1 points (low risk) 
          2 points (moderate risk) 
          3-5 points (high risk) 
   Pneumonia severity index** – median, IQR 
          Class 1-3 (low risk) 
          Class 4 (moderate risk) 
          Class 5 (high risk) 
   Intensive care unit admission 
   Invasive Mechanical ventilation 
   Death 
NA 
 
 
 
NA 
 
 
 
80/339 (24) 
94 (10)‡ 
51 (5)‡ 
1 (0-2) 
1715 (69) 
491 (20) 
275 (11) 
76 (52-103) 
1608 (65) 
652 (26) 
221 (9) 
528 (21) 
135 (5) 
53 (2) 
1 (0-2) 
1614 (70) 
444 (19) 
262 (11) 
76 (52-103) 
1510 (65) 
606 (26) 
204 (9) 
498 (21) 
131 (6) 
52 (2) 
1 (0-2) 
1431 (69) 
401 (20) 
229 (11) 
75 (52-102) 
1345 (65) 
534 (26) 
182 (9) 
445 (22) 
116 (6) 
44 (2) 
*Data were available from 4 of 5 sites and includes 943/1146 (82%) non-enrolled but eligible patients.  For ICU admission 
proportions, data were available for 2 of 5 sites and include 339/1146 (30%) non-enrolled but eligible patients.   
†Annual incidence rates were calculated from July 1, 2010 to June 30, 2011 (year 1) and July 1, 2011 to June 30, 2012 (year 2) 
‡P<0.001 when comparing eligible non-enrolled adults with those who were enrolled 
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§NA, data not available 
¶Any underlying medical condition included chronic lung disease (asthma, chronic obstructive pulmonary disease, obstructive sleep 
apnea), chronic heart disease (i.e. coronary artery disease, congestive heart failure, but not hypertension), immunosuppression (either 
due to chronic condition or medication, malignancy [but not skin cancer], human immunodeficiency virus infection with CD4 count 
>200 cells/mm3), diabetes mellitus, chronic kidney disease (with or without dialysis), neurological disorders (epilepsy, cerebral palsy, 
dementia, history of stroke), chronic liver disease (hepatitis, cirrhosis, hepatic failure), and splenectomy.   
║CURB-65 is a clinical prediction rule for community-acquired pneumonia mortality and is determined by presence of new onset 
confusion, urea >19 mg/dL, respiratory rate ≥30, systolic blood pressure <90 mmHg or diastolic blood pressure <60 mmHg, and age 
≥65 years old; one point is allotted for presence of each factor for total of five.28 
**Pneumonia severity index is a clinical prediction rule for community-acquired pneumonia related mortality based on gender, age, 
nursing home status, mental status, heart rate, respiratory rate, blood pressure, temperature, select underlying medical conditions, 
select laboratory values, and presence of pleural effusion.29 
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Supplemental Table S2: Bacterial Pathogen Detection and Timing of Inpatient and Outpatient Antibiotics* among 
Hospitalized Adults with Community-acquired Pneumonia with Available Specimen Collection Time  
Specimen Type  Proportion collected 
before antibiotics 
Positive detection 
before antibiotics 
Positive detection 
after antibiotics 
P value† 
Blood Culture‡ –  
No./Total (%)      
1607/2069 (78) 106/1607 (7) 
 
13/462 (3) 
 
0.002 
Urine antigen (S. pneumoniae) – 
No/Total (%) 
221/1941 (11) 10/221 (5) 73/1720 (4) 0.86 
Urine antigen (L. pneumophila) –  
No/Total (%) 
226/1935 (12) 5/226 (2) 26/1709 (2) 0.44 
Sputum Culture§– 
No/Total (%) 
22/271 (8) 5/22 (23) 27/249 (11) 0.10 
Pleural Fluid Culture – 
No./Total (%) 
2/75 (3) 0/2 (0) 
 
13/73 (18) 
 
1.00 
Pleural Fluid PCR – 
No./Total (%) 
1/35 (3) 0/1 (0) 
 
7/34 (21) 
 
1.00 
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NP/OP swab PCR (C. pneumonaie/ 
M. pneumoniae) – No./Total (%) 
245/2266 (11) 9/245 (4) 43/2021 (2) 
 
0.13 
*Inpatient antibiotics based on medical chart and outpatient antibiotics based on self-report and limited to ≤5 days before 
hospitalization  
†P value reflects comparisons between positive detections before and after antibiotics  
‡Enterobacteriaceae were more frequently detected in blood cultures collected before antibiotics (2% vs. 0%, P=0.005).  There were 
no significant differences in detection of S. pneumoniae, S. pyogenes, S. aureus, or H. influenzae in blood cultures collected before 
and after antibiotics.     
§Based on high-quality criteria of ≤10 epithelial cells/lpf and ≥25 white blood cells/lpf 
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Supplementary Table S3: Number of Specific Pathogen Co-detection Combinations among Hospitalized Adults with 
Community-acquired Pneumonia* 
Pathogen 
Detected† 
HRV Flu S. pn. HMPV RSV PIV CoV M. pn. S. au. AdV. Leg. Entero. Other‡ 
HRV 161 6 14 2 2 2 6 2 0 1 1 0 2 
Flu 6 108 4 1 0 3 1 1 3 1 0 0 2 
S. pn. 14 4 80 7 2 7 2 0 0 0 1 0 1 
HMPV 2 1 7 67 4 4 0 1 1 2 0 0 2 
RSV 2 0 2 4 55 3 1 1 1 0 0 1 1 
PIV 2 3 7 4 3 41 1 1 2 3 0 0 3 
CoV 6 1 2 0 1 1 38 0 1 1 2 0 1 
M. pn. 2 1 0 1 1 1 0 37 1 0 0 0 0 
S. au. 0 3 0 1 1 2 1 1 24 0 0 3 2 
AdV. 1 1 0 2 0 3 1 0 0 22 0 0 2 
Leg. 1 0 1 0 0 0 2 0 0 0 28 0 0 
Entero. 0 0 0 0 1 0 0 0 3 0 0 25 2 
Other‡ 2 2 1 2 1 3 1 0 2 2 0 2 57 
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*Among the 2259 with at least one specimen available for bacterial and viral testing.  
†Human rhinovirus (HRV), influenza A/B (Flu), S. pneumoniae (S. pn.) , human metapneumovirus (HMPV), respiratory syncytial 
virus (RSV), parainfluenza viruses 1-3 (PIV), coronaviruses (CoV), M. pneumoniae (M. pn.),  S. aureus (S. au.), adenovirus (AdV), L. 
pneumophila (Leg.), Enterobacteriaceae (Entero.)  
‡76 other detections in 74 patients (12 H. influenzae, 9 C. pneumoniae, 8 M. tuberculosis, 8 pseudomonas, 7 S. pyogenes, 7 viridans 
group streptococci, 7 other Streptococcus spp., 4 nontuberculous mycobacterial species, 3 Fusobacterium, 3 Pneumocystis jirovecii, 1 
each of bacteroides, coccidioides, histoplasma, pasteurella,1 H. influenzae/Neisseria Meningitidis,1 viridans group streptococci/other 
Streptococcus spp.). 
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Supplementary Table S4A/B: Number of Specific Pathogens Detected among Hospitalized 
Adults with Community-acquired Pneumonia by Sample Type*  
Pathogen detected (total detected) NP/OP PCR 
only 
(n=2247) 
Serology 
only 
(n=854) 
Both NP/OP PCR and 
serology 
(n=2259) 
Human rhinovirus (n=194) 194 NA† NA 
Influenza A/B (n=132) 91 22/846 19 
Human metapneumovirus (n=88) 63 9 16 
Respiratory syncytial virus (n=68) 46 10 12 
Parainfluenza viruses 1-3 (n=67) 45 11 11 
Coronaviruses (n=53) 53 NA NA 
M. pneumoniae (n=43) 43 NA NA 
Adenovirus (n=32) 20 8 4 
Pathogen 
detected  
(total detected) 
Blood 
culture 
only 
(n=2070) 
Urine 
antigen  
only 
(n=1923) 
Sputum 
culture or 
PCR only 
BAL 
culture 
only 
(n=83) 
Pleural fluid 
culture 
only 
 (n=71) 
Pleural 
fluid PCR 
only 
(n=35) 
More than 
one 
modality‡ 
(n=2259) 
S. pneumoniae 
(n=115) 
26 56§ 8/267 high-
quality by 
culture 
3 1 0 21 
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*Among those with at least one specimen type available for both bacterial and viral testing 
†NA = not applicable 
‡Detection by more than one modality: Among 21 S. pneumoniae detections by more than one 
modality, 16 were by blood culture and urine antigen, 4 by high-quality sputum culture and urine 
antigen, and 1 by pleural fluid PCR and urine antigen.  Among 3 S. aureus detections by more 
than one modality, 1 was by high-quality sputum culture and pleural fluid culture, 1 by pleural 
fluid culture, pleural fluid PCR, and BAL culture, and 1 by blood culture and BAL culture.  
Among 6 Legionella detections by more than one modality, 6 were by sputum PCR and urine 
antigen. 
§Two patients may be false-positive based on timing of pneumococcal vaccination and urine 
collection.6 
 
 
   
S. aureus 
(n=37) 
20 NA 10/267 
high-quality 
by culture 
4 0 0 3 
L. pneumophila 
(n=32) 
NA 25/1912 1/953 any 
quality by 
PCR 
NA NA NA 6 
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Supplemental Table S5: Pathogen Detection among Hospitalized Adults with Community-
acquired Pneumonia by Age Group* 
Pathogen detected 18-49 
years 
(n=681) 
50-64 
years 
(n=773) 
65-79 
years 
(n=506) 
≥ 80 
years 
(n=299) 
All ages 
(n=2259) 
Any detection 41% 36% 39% 34% 38% 
Any co-detection† 5% 5% 4% 3% 5% 
Human rhinovirus 11% 7% 8% 9% 9% 
Influenza A/B 7% 6% 4% 5% 6% 
S. pneumoniae 5% 5% 7% 3% 5% 
Human metapneumovirus 4% 3% 5% 2% 4% 
Respiratory syncytial virus 2% 3% 4% 4% 3% 
Parainfluenza viruses 1-3 2% 4% 2% 4% 2% 
Coronaviruses 2% 2% 3% 3% 2% 
M. pneumoniae 4% 1% 1% 1% 2% 
S. aureus 1% 2% 1% 1% 2% 
Adenovirus 1% 2% 1% 1% 1% 
L. pneumophila 1% 2% 1% 1% 1% 
Enterobacteriaceae 1% 1% 2% 2% 1% 
*Among those with at least one specimen available for bacterial and viral testing. 
†Co-detection is defined as any combination of bacteria, virus, fungal, or mycobacterial detection 
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Supplemental Table S6: Pathogen Detection among Hospitalized Adults with Community-
acquired Pneumonia by Pneumonia Severity Index (PSI) and Intensive Care Unit (ICU) 
Admission* 
Pathogen detected PSI I-III 
(n=1475) 
PSI IV-V 
(n=784) 
P value† Non-ICU  
(n=1777) 
ICU  
(n=482) 
P value‡ 
Any detection 38% 37% 0.65 36% 45% <0.001 
Any co-detection§ 5% 5% 0.66 4% 7% 0.003 
Viral detection only 25% 21% 0.03 24% 22% 0.27 
Bacterial detection 
only 
10% 13% 0.006 9% 19% <0.001 
Bacterial-viral co-
detection  
3% 3% 0.90 2% 4% 0.04 
Human rhinovirus 9% 7% 0.07 9% 8% 0.42 
Influenza A/B 7% 4% 0.02 6% 6% 0.97 
S. pneumoniae 4% 7% 0.02 4% 8% <0.001 
Human 
metapneumovirus 
4% 3% 0.30 4% 3% 0.32 
Respiratory 
syncytial virus 
3% 4% 0.26 3% 4% 0.18 
Parainfluenza 
viruses 1-3 
3% 3% 0.95 3% 4% 0.04 
Coronaviruses 2% 3% 0.64 2% 3% 0.57 
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M. pneumoniae 3% 1% 0.001 2% 1% 0.06 
S. aureus 1% 3% 0.001 1% 5% <0.001 
Adenovirus 1% 1% 0.68 2% <1% 0.05 
L. pneumophila 2% 1% 0.06 2% 1% 0.43 
Enterobacteriaceae 1% 2% 0.002 1% 3% <0.001 
*Among the 2259 with at least one specimen available for bacterial and viral testing 
†P value comparing proportion of each detection between PSI I-III and PSI IV-V   
‡P value comparing proportion of each detection between non-ICU and ICU admission 
§Co-detection is defined as any combination of bacteria, virus, fungal, or mycobacterial detection 
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Supplementary Table S7: Comparison of Adults with Radiographic Pneumonia with 
Enrolled Controls* 
Characteristic All adults 
with 
radiographic 
pneumonia 
(n=2320) 
Adults with 
radiographic 
pneumonia in 
Nashville 
during period of 
control 
enrollment 
(n=192) 
Asymptomatic 
adult controls† 
(n=238) 
All adult 
controls‡ 
(n=262) 
Female 1190 (51) 114 (59) 129 (54) 143 (55) 
Race and ethnicity 
     Non-Hispanic white 
     Non-Hispanic black 
     Hispanic 
     Other 
 
1086 (47) 
898 (39) 
243 (10) 
93 (4) 
 
129 (67) 
54 (28) 
7 (4) 
2 (1) 
 
177 (74) 
48 (20) 
5 (2) 
8 (3) 
 
194 (74) 
53 (20) 
6 (2) 
9 (3) 
Age median (IQR) 57 (46-71) 59 (50-72) 54 (41-65) 54 (40-64) 
Age group 
     18-49 years 
     50-64 years 
     65-79 years 
     ≥ 80 years 
 
701 (30) 
787 (34) 
517 (22) 
315 (14) 
 
43 (22) 
75 (39) 
47 (24) 
27 (14) 
 
97 (41) 
80 (34) 
54 (23) 
7 (3) 
 
110 (42) 
88 (34) 
56 (21) 
8 (3) 
Select underlying condition§ – no. (%)     
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    Chronic lung disease     
    Diabetes mellitis     
    Chronic heart disease 
    Immunosuppression   
799 (34) 
545 (24) 
685 (30) 
551 (24) 
87 (45) 
55 (29) 
46 (24) 
50 (26) 
32 (13) 
42 (18) 
23 (10) 
23 (10) 
36 (14) 
46 (18) 
25 (10) 
27 (10) 
*Controls were only enrolled Vanderbilt University Medical Center from November 1, 2011-
June 30, 2012 
†There were only 5 detections among the asymptomatic controls and included: 2 human 
rhinovirus, 2 coronaviruses, and 1 human metapneumovirus 
‡All adult controls include controls that subsequently developed symptoms within 14 days after 
enrollment 
§Because controls were outpatients, underlying conditions was only assessed by patient interview 
for a limited number of conditions.  Thus the underlying conditions depicted here are based on 
only patient interview for both controls and adults with radiographic pneumonia. 
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Supplementary Table S8: Comparison of Adults with Radiographic Pneumonia in the 
Study Cities 
Characteristic Chicago 
(n=1538) 
Nashville 
(n=782) 
P value 
Female sex – no. (%) 776 (51) 414 (47) 0.26 
Race and ethnicity – no. (%) 
     Non-Hispanic white 
     Non-Hispanic black 
     Hispanic 
     Other 
 
580 (38) 
655 (43) 
224 (15) 
79 (5) 
 
506 (65) 
243 (31) 
19 (2) 
14 (2) 
<0.001 
Age groups – no. (%) 
    18-49 years 
    50-64 years 
    65-79 years 
    ≥ 80 years 
 
487 (32) 
528 (34) 
315 (21) 
208 (14) 
 
214 (27) 
259 (33) 
202 (26) 
107 (14) 
0.02 
Hospital indicators – no. (%) 
     Length of stay – median days, IQR 
     CURB-65 – median, IQR 
          0-1 points (low risk) 
          2 points (moderate risk) 
          3-5 points (high risk) 
     PSI – median, IQR 
          Class 1-3 (low risk) 
 
3 (2-6)  
1 (0-2) 
1063 (71) 
284 (19) 
160 (11) 
74 (51-102) 
995 (66) 
 
3 (2-6) 
1 (0-2) 
513 (68) 
147 (20) 
92 (12) 
78 (54-105) 
480 (64) 
 
0.87 
0.10 
0.43 
 
 
0.42 
0.49 
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          Class 4 (moderate risk) 
          Class 5 (high risk) 
     ICU admission 
     Mechanical ventilation 
     Death 
380 (25) 
132 (9) 
327 (22) 
88 (6) 
29 (2) 
207 (28) 
65 (9) 
155 (21) 
38 (5) 
20 (3) 
 
 
0.55 
0.48 
0.26 
Pathogens Detected    
     Any detection 559 (37) 294 (39) 0.36 
     Any co-detection§ 84 (6) 26 (3) 0.03 
     Viral only 339 (23) 191 (25) 0.13 
     Bacterial only 158 (11) 89 (12) 0.33 
     Viral-Bacterial  46 (3) 13 (2) 0.06 
     Human rhinovirus 124 (8) 70 (9) 0.39 
     Influenza A/B 92 (6) 40 (5) 0.45 
     S. pneumoniae 72 (5) 43 (6) 0.34 
     Human metapneumovirus 60 (4) 28 (4) 0.77 
     Respiratory syncytial virus 44 (3) 24 (3) 0.72 
     Parainfluenza viruses 1-3 44 (3) 23 (3) 0.86 
     Coronaviruses 34 (2) 19 (3) 0.69 
     M. pneumoniae 33 (2) 10 (1) 0.16 
     S. aureus 27 (2) 10 (1) 0.42 
     Adenovirus 18 (1) 14 (2) 0.21 
     L. pneumophila 20 (1) 12 (2) 0.61 
     Enterobacteriaceae 24 (2) 7 (1) 0.20 
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